Medpace Share Price (NASDAQ: MEDP)

$473.55

▲

4.26

(0.91%)

Live

Last updated on August 28, 2025 at 12:38 am IST

$₹

Check the interactive Medpace Stock chart to analyse performance

Medpace stock performance

as on August 28, 2025 at 12:38 am IST

Today's Low:$470.84
Today's High:$474.92
$473.55
0.57%
Downside
Day's Volatility :0.86%
Upside
0.29%
52 Weeks Low:$250.05
52 Weeks High:$501.30
$473.55
47.2%
Downside
52 Weeks Volatility :50.12%
Upside
5.54%

Medpace Stock Returns

Period	Medpace Holdings, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	59.75%	3.7%	0.0%
6 Months	38.26%	-6.9%	0.0%
1 Year	22.44%	-11.9%	0.0%
3 Years	202.7%	7.7%	-6.9%

Medpace Holdings, Inc. Key Stats

Check Medpace key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$469.29
Open	$467.32
Today's High	$474.92
Today's Low	$470.84
Market Capitalization	$13.1B
Today's Volume	$239.0K
52 Week High	$501.2999
52 Week Low	$250.05
Revenue TTM	$2.2B
EBITDA	$506.5M
Earnings Per Share (EPS)	$13.45
PE Ratio	34.71
Profit Margin	18.74%
Quarterly Earnings Growth YOY	0.13%
Return On Equity TTM	89.39%

Stock Returns calculator for Medpace Stock including INR - Dollar returns

The Medpace stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Medpace investment value today

Current value as on today

₹1,28,199

Returns

₹28,199

(+28.2%)

Returns from Medpace Stock

₹23,526 (+23.53%)

Dollar Returns*

₹4,673 (+4.67%)

Indian investors sentiment towards Medpace Stock

-58%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Medpace Stock from India on INDmoney has decreased by -58% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Medpace Holdings, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
9.57%
Vanguard Group Inc
8.51%
Amvescap Plc.
4.22%
Wasatch Advisors LP
3.37%
Mawer Investment Management Ltd
2.91%
State Street Corp
2.79%

Analyst Recommendation on Medpace Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Medpace(by analysts ranked 0 to 5 stars)

Medpace Share Price Target

What analysts predicted

Downside of 13.36%

Target:

$410.27

Current:

$473.55

Medpace share price target is $410.27, a slight Downside of 13.36% compared to current price of $473.55 as per analysts' prediction.

Medpace Stock Insights

Price Movement
In the last 3 months, MEDP stock has moved up by 57.2%
Increasing Revenue
Revenue is up for the last 21 quarters, 204.99M → 603.31M (in $), with an average increase of 5.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 117.01M → 90.26M (in $), with an average decrease of 11.7% per quarter
MEDP vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 33.0% return, outperforming this stock by 10.6%
Price to Sales
ForMEDP every $1 of sales, investors are willing to pay $6.4, whereas for Idexx Laboratories, Inc., the investors are paying $12.9 for every $1 of sales.

Medpace Holdings, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$861.0M	↑ 22.19%
Net Income	$100.4M	↑ 37.25%
Net Profit Margin	11.67%	↑ 1.28%

	FY20	Y/Y Change
Revenue	$925.9M	↑ 7.54%
Net Income	$145.4M	↑ 44.74%
Net Profit Margin	15.7%	↑ 4.03%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 23.38%
Net Income	$181.8M	↑ 25.08%
Net Profit Margin	15.92%	↑ 0.22%

	FY22	Y/Y Change
Revenue	$1.5B	↑ 27.8%
Net Income	$245.4M	↑ 34.93%
Net Profit Margin	16.81%	↑ 0.89%

	FY23	Y/Y Change
Revenue	$1.9B	↑ 29.17%
Net Income	$282.8M	↑ 15.26%
Net Profit Margin	15.0%	↓ 1.81%

	FY24	Y/Y Change
Revenue	$2.1B	↑ 11.84%
Net Income	$404.4M	↑ 42.99%
Net Profit Margin	19.17%	↑ 4.17%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$511.0M	↑ 2.54%
Net Income	$102.6M	↑ 31.03%
Net Profit Margin	20.07%	↑ 4.36%

	Q2 FY24	Q/Q Change
Revenue	$528.1M	↑ 3.34%
Net Income	$88.4M	↓ 13.88%
Net Profit Margin	16.73%	↓ 3.34%

	Q3 FY24	Q/Q Change
Revenue	$533.3M	↑ 0.99%
Net Income	$96.4M	↑ 9.14%
Net Profit Margin	18.08%	↑ 1.35%

	Q4 FY24	Q/Q Change
Revenue	$536.6M	↑ 0.61%
Net Income	$117.0M	↑ 21.36%
Net Profit Margin	21.81%	↑ 3.73%

	Q1 FY25	Q/Q Change
Revenue	$558.6M	↑ 4.1%
Net Income	$114.6M	↓ 2.07%
Net Profit Margin	20.52%	↓ 1.29%

	Q2 FY25	Q/Q Change
Revenue	$603.3M	↑ 8.01%
Net Income	$90.3M	↓ 21.24%
Net Profit Margin	14.96%	↓ 5.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$245.7M	↑ 14.0%

	FY20	Y/Y Change
Profit	$278.7M	↑ 13.44%

	FY21	Y/Y Change
Profit	$328.2M	↑ 17.73%

	FY22	Y/Y Change
Profit	$432.4M	↑ 31.78%

	FY23	Y/Y Change
Profit	$524.5M	↑ 21.29%

	FY24	Y/Y Change
Profit	$656.3M	↑ 25.13%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$155.1M	↑ 13.4%

	Q2 FY24	Q/Q Change
Profit	$153.8M	↓ 0.84%

	Q3 FY24	Q/Q Change
Profit	$169.0M	↑ 9.86%

	Q4 FY24	Q/Q Change
Profit	$178.3M	↑ 5.51%

	Q1 FY25	Q/Q Change
Profit	$178.4M	↑ 0.02%

	Q2 FY25	Q/Q Change
Profit	$180.0M	↑ 0.93%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$201.9M	↑ 28.92%
Investing Cash Flow	$-19.1M	↑ 12.79%
Financing Cash Flow	$-73.9M	↓ 47.79%

	FY20	Y/Y Change
Operating Cash Flow	$258.7M	↑ 28.14%
Investing Cash Flow	$-31.2M	↑ 63.05%
Financing Cash Flow	$-82.3M	↑ 11.32%

	FY21	Y/Y Change
Operating Cash Flow	$263.3M	↑ 1.8%
Investing Cash Flow	$-31.4M	↑ 0.48%
Financing Cash Flow	$-44.5M	↓ 45.97%

	FY22	Y/Y Change
Operating Cash Flow	$388.1M	↑ 47.36%
Investing Cash Flow	$-38.7M	↑ 23.52%
Financing Cash Flow	$-775.8M	↑ 1645.16%

	FY23	Y/Y Change
Operating Cash Flow	$433.4M	↑ 11.68%
Investing Cash Flow	$-34.6M	↓ 10.62%
Financing Cash Flow	$-182.6M	↓ 76.46%

	FY24	Y/Y Change
Operating Cash Flow	$608.8M	↑ 40.48%
Investing Cash Flow	$-28.3M	↓ 18.25%
Financing Cash Flow	$-154.0M	↓ 15.68%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$152.7M	↓ 2.38%
Investing Cash Flow	$2.5M	↓ 131.64%
Financing Cash Flow	$7.7M	↑ 402.95%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$116.4M	↓ 23.76%
Investing Cash Flow	$-12.8M	↓ 605.53%
Financing Cash Flow	$666.0K	↓ 91.31%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$149.1M	↑ 28.07%
Investing Cash Flow	$-10.5M	↓ 18.01%
Financing Cash Flow	$6.3M	↑ 842.04%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$190.7M	↑ 27.9%
Investing Cash Flow	$-7.6M	↓ 27.88%
Financing Cash Flow	$-168.6M	↓ 2787.42%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$125.8M	↓ 34.0%
Investing Cash Flow	$-10.0M	↑ 32.07%
Financing Cash Flow	$-346.0M	↑ 105.19%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$148.5M	↑ 18.03%
Investing Cash Flow	$-6.0M	↓ 39.72%
Financing Cash Flow	$-540.6M	↑ 56.25%

Medpace Technicals Summary

Sell

Neutral

Buy

Medpace is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Medpace Holdings, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Medpace Holdings, Inc.	3.6%	38.26%	22.44%	202.7%	267.13%
Agilent Technologies Inc.	-1.05%	-12.03%	-16.17%	-7.67%	18.41%
Idexx Laboratories, Inc.	13.27%	40.16%	32.97%	83.83%	67.11%
Thermo Fisher Scientific, Inc.	0.75%	-8.38%	-19.96%	-12.23%	15.1%
Danaher Corp.	1.65%	-1.5%	-23.26%	-25.44%	0.32%
Iqvia Holdings Inc.	-5.01%	-1.62%	-24.44%	-13.91%	16.52%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Medpace Holdings, Inc.	34.71	34.71	3.9	14.37	0.89	0.17	NA	6.15
Agilent Technologies Inc.	29.14	29.14	1.75	5.58	0.19	0.08	0.01	21.61
Idexx Laboratories, Inc.	53.4	53.4	4.83	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.37	28.37	2.04	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	44.2	44.2	2.12	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.21	27.21	1.08	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Medpace Holdings, Inc.	Buy	$13.1B	267.13%	34.71	18.74%
Agilent Technologies Inc.	Buy	$33.6B	18.41%	29.14	17.59%
Idexx Laboratories, Inc.	Buy	$51.3B	67.11%	53.4	24.41%
Thermo Fisher Scientific, Inc.	Buy	$185.3B	15.1%	28.37	15.24%
Danaher Corp.	Buy	$148.7B	0.32%	44.2	14.21%
Iqvia Holdings Inc.	Buy	$31.9B	16.52%	27.21	7.88%

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Organization	Medpace
Employees	6000
CEO	Dr. August James Troendle M.D.
Industry	Commercial Services

Key Management of Medpace Holdings, Inc.

Name	Title
Dr. August James Troendle M.D.	Chairman & CEO
Mr. Jesse J. Geiger BBA, CPA	President
Mr. Kevin M. Brady	CFO & Treasurer
Ms. Susan E. Burwig BSN, MA	Executive Vice President of Operations
Mr. Stephen P. Ewald J.D.	Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Brandon Ebken	Chief Information Officer
Ms. Lauren Morris	Associate Director of Investors Relations
Mr. Todd Meyers	Vice President of Business Development & Marketing
Mr. Weimin Gai MS	Senior Vice President of Biometrics
Mr. John T. Wynne MBA	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit

Important FAQs about investing in MEDP Stock from India :

What is Medpace share price today?

Medpace share price today is $473.55 as on August 28, 2025 at 12:38 am IST. Medpace share today touched a day high of $474.92 and a low of $470.84.

What is the 52 week high and 52 week low for Medpace share?

Medpace share touched a 52 week high of $501.30 and a 52 week low of $250.05. Medpace stock price today i.e. August 28, 2025 at 12:38 am IST is trending at $473.55, lower by 5.54% versus the 52 week high.

How to invest in Medpace Stock (MEDP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Medpace on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Medpace Shares that will get you 0.0032 shares as per Medpace share price of $473.55 per share as on August 28, 2025 at 12:38 am IST.

What is the minimum amount required to buy Medpace Stock (MEDP) from India?

Indian investors can start investing in Medpace (MEDP) shares with as little as ₹87.86 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Medpace stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Medpace share’s latest price of $473.55 as on August 28, 2025 at 12:38 am IST, you will get 0.0211 shares of Medpace. Learn more about fractional shares .

What are the returns that Medpace has given to Indian investors in the last 5 years?

Medpace stock has given 267.13% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?